10/15/2026
🍷 GLP-1 MEDICATIONS: TURNING DOWN THE VOLUME ON ALCOHOL CRAVINGS?
What if a medication designed to treat diabetes and obesity could also help reduce alcohol cravings? Emerging research suggests GLP-1 receptor agonists, including semaglutide (Ozempic/Wegovy/Mounjaro/Zepbound), may do exactly that.
🧠 It’s not just about appetite. It’s about the brain.
GLP-1 receptors are involved in the brain’s reward and motivation pathways. These medications may reduce the reinforcing effects of alcohol, potentially decreasing cravings and excessive drinking.
🔬 A 2025 randomized clinical trial published in JAMA Psychiatry found that low-dose semaglutide reduced alcohol craving, drinking quantity, and heavy-drinking outcomes in adults with alcohol use disorder.
🔬 Additional observational studies suggest GLP-1 medications may be associated with fewer alcohol-related complications. But here’s the important distinction:
Reducing alcohol cravings is NOT the same as treating alcohol addiction. These medications are promising, but larger clinical trials are needed. GLP-1 agonists are not currently FDA-approved treatments for alcohol use disorder.
Additionally, CaloCurb, the only GLP-1 supplement that has human studies showing effective appetite suppression and weight loss, WITHOUT the muscle loss seen with GLP-1 medications, has also helped with alcohol cravings! My takeaway:
We may be discovering that GLP-1 medications do far more than regulate blood sugar and body weight. They may influence the neurological pathways driving cravings, reward, and addictive behaviors. Perhaps the next frontier of metabolic medicine isn’t just what we eat. It’s understanding why we crave.
Less craving. More control. Better health.